Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results

Nuvectis Pharma (NASDAQ:NVCT) posted its quarterly earnings data on Tuesday. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08), Zacks reports.

Nuvectis Pharma Stock Down 0.7 %

Nuvectis Pharma stock traded down $0.06 during trading hours on Tuesday, reaching $7.31. 13,615 shares of the company’s stock were exchanged, compared to its average volume of 118,166. The firm’s 50 day simple moving average is $6.14 and its 200 day simple moving average is $6.40. Nuvectis Pharma has a twelve month low of $4.44 and a twelve month high of $12.10. The firm has a market capitalization of $141.13 million, a PE ratio of -6.30 and a beta of 0.22.

Insider Activity at Nuvectis Pharma

In related news, major shareholder Marlio Charles Mosseri bought 17,000 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average price of $4.70 per share, for a total transaction of $79,900.00. Following the transaction, the insider now directly owns 2,612,000 shares of the company’s stock, valued at approximately $12,276,400. The trade was a 0.66 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired a total of 261,500 shares of company stock worth $1,300,825 in the last 90 days. Corporate insiders own 35.78% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.